Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult MC Programs in Zimbabwe

Overview

The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe

Full Title of Study: “Phase I of Study of Safety and Efficacy of the PrePex Device for MC Programs in Zimbabwe”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2011

Detailed Description

Models show that to have the highest impact on the HIV epidemic, circumcision of up to 80% of men in high prevalence countries, where MC rates are low, needs to be achieved (UNAIDS 2009; Manicaland HIV/STD Prevention Project, 2008; Bollinger, et al, 2009). Hallett and colleagues in 2008 showed that for Zimbabwe specifically, HIV incidence could be reduced between 25% to 35% if about 50% of men are circumcised. All modelings conducted show that MC programs must be part of a comprehensive HIV prevention package as MC alone will not tip the HIV epidemic into a terminal decline. The PrePex Device offers hope for rapid scale up of adult male circumcision in resource limited settings. Once the safety and efficacy have been established, it is important to conduct operations research to determine how best to implement both device and surgical circumcisions in the national program. Thus, the Zimbabwe MOHCW is planning a three phase trial in order to determine the safety of the PrePexTM device, its performance and the ease of use in an implementation roll out.

Interventions

  • Device: PrePex™ device
    • PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia

Arms, Groups and Cohorts

  • Experimental: Experimental: PrePex™ device
    • Adult male circumcision by the PrePex™ device

Clinical Trial Outcome Measures

Primary Measures

  • The Safety and Efficacy of the PrePex Device for adult male circumcision in Zimbabwe
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • Outcome measures include: Clinical adverse events and device-related incidents

Secondary Measures

  • Evaluating the procedure duration
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • The total procedure and preparation time of the PrePex™ device circumcision procedure
  • Evaluating the pain at key time points
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • Pain assessment at key time points using Visual Analog Scale (VAS)
  • Evaluating the discomfort during daily activities
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • using questionnaires
  • Evaluating the compliance during use (with follow-up)
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • compliance during use (with follow-up)using questionnaires
  • Evaluating the procedure acceptability by Doctors
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • procedure acceptability by Doctors using questionnaires
  • Glans fully exposed
    • Time Frame: 8 week post-procedure follow up appointment and examination
  • Evaluating time to complete healing
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • time to complete healing using wound assessment
  • Evaluating the cosmetic results
    • Time Frame: 8 week post-procedure follow up appointment and examination
  • Procedure acceptability by Nurses
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • Procedure acceptability by Nurses using questionnaires
  • Satisfaction by subjects
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • Satisfaction by subjects
  • Satisfaction by providers
    • Time Frame: 8 week post-procedure follow up appointment and examination
    • using questionnaires

Participating in This Clinical Trial

Inclusion Criteria

  • Ages 18 – 30 years – Uncircumcised – Wants to be circumcised – Agrees to be circumcised by any of the study methods,PrePex or Surgical as appropriate – HIV sero-negative – Able to understand the study procedures and requirements – Agrees to abstain from sexual intercourse and to keep caution not to directly rub the cut area if masturbating, for 8 weeks post removal (9 weeks total) – Agrees to return to the health care facility for follow-up visits (or as instructed) after his circumcision for a period of 8 weeks post removal (9 weeks total) – Subject able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have good compliance for the study – Subject agrees to anonymous video and photographs of the procedure and follow up visits – Agrees to stay overnight at the Hospital in order to follow pain measurements in the first 16 hours Exclusion Criteria:

  • Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the subject from undergoing a circumcision – HIV sero-positive – Subject with the following diseases/conditions: phimosis, paraphimosis, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias – Known bleeding / coagulation abnormality – Uncontrolled diabetes – Subject that to the opinion of the investigator is not a good candidate – Subject does not agree to anonymous video and photographs of the procedure and follow up visits – Refusal to take HIV test.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Ministry of Health and Child Welfare, Zimbabwe
  • Provider of Information About this Clinical Study
    • Principal Investigator: Prof. Mufuta Tshimanga, Public Health Physician, Department of Community Medicine, University of Zimbabwe – Ministry of Health and Child Welfare, Zimbabwe
  • Overall Official(s)
    • Gerald Gwinji, MBChB, MPH, Principal Investigator, PS- MoHCW

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.